International law firm Taylor Wessing has advised Glenmark, the Mumbai-headquartered pharmaceutical company, on the sale of its central nervous system (CNS) product portfolio business in Poland.
The portfolio has been sold to Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of CNS disorders.
The Glenmark CNS commercial team in Poland has also joined Neuraxpharm Polska’s existing sales and marketing organisation to create a strong player in the Polish CNS market.
Glenmark’s established portfolio of 20 proprietary CNS products comprise both prescription medicines and Consumer Healthcare products. Lead products include the branded generics Cital® and Lamotrix®, both relevant brands in their respective markets.
This complex transaction drew on the deep expertise offered by the firm’s market-leading life sciences M&A practice including lawyers from both the corporate and intellectual property teams.
Commenting on the deal, Emma Danks, Co-head of International Corporate at Taylor Wessing said: “Glenmark is a leader in CNS products, and it makes good commercial sense that Neuraxpharm sees the opportunity to incorporate Glenmark's portfolio into its own business. This was a very exciting deal to have worked on as it hits our sweet spot, leveraging our specialist knowledge of the life sciences and pharmaceutical sectors together with our cross-border M&A expertise, with an international Taylor Wessing team from the United Kingdom, Poland and the Czech Republic."
The team was led by corporate partner Emma Danks and intellectual property partner Colin McCall with the support of corporate associate Nick Karangizi and intellectual property associate Lucy Sharples in the United Kingdom.
In addition, partner Graham Samuel-Gibbon and associate Madison Lawler advised on tax, and partner Jason Rawkins and associate Simon Jupp advised on intellectual property matters.
Further advice was given by corporate partner Olav Nemling, employment partner Krystian Stanasiuk, tax counsel Marcin Sroga, intellectual property senior associate Dr.Agnieszka Sztoldman in Poland and corporate partner Janka Brezaniova in the Czech Republic.